中医临床研究
中醫臨床研究
중의림상연구
CLINICAL JOURNAL OF CHINESE MEDICINE
2015年
2期
11-14
,共4页
心脉隆注射液%慢性心力衰竭%Meta分析
心脈隆註射液%慢性心力衰竭%Meta分析
심맥륭주사액%만성심력쇠갈%Meta분석
Xinmailong injection%Chronic heart hailure%Meta-analysis
目的：评价心脉隆注射液治疗慢性心力衰竭的疗效及安全性。方法：按照循证医学的要求，全面检索并选取中国知网及万方数据库公开发表的有关心脉隆注射液治疗慢性心力衰竭的随机对照试验研究（RCT），按纳入与排除标准选择试验、评价质量，提取资料，选择心脏彩超左室射血分数（LVEF）及血BNP浓度的变化作为效应指标。采用Jadad评分法进行质量评价，并用RevMan5.2软件对数据进行Meta分析。结果：共检出106篇相关文献，经筛选最终纳入10篇关于心脉隆注射液治疗慢性心力衰竭的随机对照研究，经Meta分析后显示，在提高LVEF值及降低BNP水平方面优于对照组，且耐受性亦好。漏斗图显示不对称，提示存在一定的发表偏倚。结论：现有的临床证据证明心脉隆注射液组治疗慢性心力衰竭优于对照组，且药物副作用小，在安全性方面有较高的临床价值。但由于现有研究质量较差，尚需要设计严格、大样本的RCT加以证实。
目的：評價心脈隆註射液治療慢性心力衰竭的療效及安全性。方法：按照循證醫學的要求，全麵檢索併選取中國知網及萬方數據庫公開髮錶的有關心脈隆註射液治療慢性心力衰竭的隨機對照試驗研究（RCT），按納入與排除標準選擇試驗、評價質量，提取資料，選擇心髒綵超左室射血分數（LVEF）及血BNP濃度的變化作為效應指標。採用Jadad評分法進行質量評價，併用RevMan5.2軟件對數據進行Meta分析。結果：共檢齣106篇相關文獻，經篩選最終納入10篇關于心脈隆註射液治療慢性心力衰竭的隨機對照研究，經Meta分析後顯示，在提高LVEF值及降低BNP水平方麵優于對照組，且耐受性亦好。漏鬥圖顯示不對稱，提示存在一定的髮錶偏倚。結論：現有的臨床證據證明心脈隆註射液組治療慢性心力衰竭優于對照組，且藥物副作用小，在安全性方麵有較高的臨床價值。但由于現有研究質量較差，尚需要設計嚴格、大樣本的RCT加以證實。
목적：평개심맥륭주사액치료만성심력쇠갈적료효급안전성。방법：안조순증의학적요구，전면검색병선취중국지망급만방수거고공개발표적유관심맥륭주사액치료만성심력쇠갈적수궤대조시험연구（RCT），안납입여배제표준선택시험、평개질량，제취자료，선택심장채초좌실사혈분수（LVEF）급혈BNP농도적변화작위효응지표。채용Jadad평분법진행질량평개，병용RevMan5.2연건대수거진행Meta분석。결과：공검출106편상관문헌，경사선최종납입10편관우심맥륭주사액치료만성심력쇠갈적수궤대조연구，경Meta분석후현시，재제고LVEF치급강저BNP수평방면우우대조조，차내수성역호。루두도현시불대칭，제시존재일정적발표편의。결론：현유적림상증거증명심맥륭주사액조치료만성심력쇠갈우우대조조，차약물부작용소，재안전성방면유교고적림상개치。단유우현유연구질량교차，상수요설계엄격、대양본적RCT가이증실。
Objective: To evaluate effects and safety of Xinmailong injection on treating chronic heart hailure. Methods: According to the requirements of evidence-based medicine,randomized controlled trials about Xinmailong injection in the treatment of chronic heart hailure were comprehensive searched and retrieved to screen the qualified researches, and according to including and excluding standards, percent test, LVEF and BNP concentration changing were regarded as the effect index. Jadad scores were used to evaluate the quality and the data was statistically analyzed by Meta-analysis with RevMan 5.2 software. Results: In the 106 pieces of literature, 10 studies were incorporated by Meta-analysis and results showed that the Xinmailong injection group was better than control group in increasing LVEF and reducing the numbers of BNP, and tolerance is also good. Funnel figures suggested that there were some publication bias. Conclusion: The existing clinical evidences proved that the Xinmailong injection group was better than the control group on treating chronic heart hailure, with clinical value of safety and fewer side effects, because of poor quality of present researches,these results need to be verified by strictly-designed and large-scale sample randomized control trial.
